Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

Clinical Infectious Diseases

Volumn 42, Issue 5, 2006, Pages 597-607

  Jaksic, Branimir ^a   Martinelli, Giovanni ^b   Perez Oteyza, Jaime ^c   Hartman, Charlotte S ^d   Leonard, Linda B ^d   Tack, Kenneth J ^d  

^a University of Zagreb   (Croatia)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VOMITING;

EID: 33144464478     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500139     Document Type: Article

References (25)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
2. Gibson J, Johnson L, Snowdon L, et al. Trends in bacterial infections in febrile neutropenic patients: 1986-1992. Aust N Z J Med 1994; 24: 374-7.
3. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247-59.
4. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319:1053-8.
5. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
6. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340:493-501.
7. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996; 39:673-9.
8. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.
9. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
10. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
11. Weigelt JA, Itani KM, Lau WK, Somero MS. Linezolid vs vancomycin in the treatment of complicated skin and soft tissue infections (CSSTI): clinically significant outcome differences [abstract 314]. In: Program and abstracts of the 40th Annual Meeting of the Infectious Disease Society of America (San Diego). Alexandria, VA: Infectious Diseases Society of America, 2003:87.
12. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
13. Stevens DL, Harrison M, Graham DR, Glick HA, Birmingham MC. Linezolid (LZD) IV/PO vs. Vancomycin (Vanco) IV for the treatment of suspected or proven methicillin-resistant Staphylococcus spp. (MRSS) infections: a second randomized, open-label, clinical trial [abstract 181]. In: Program and abstracts of the 40th Annual Meeting of the Infectious Disease Society of America (Chicago). Alexandria, VA: Infectious Diseases Society of America, 2002:76.
14. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62:1037-40.
15. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982; 3:345-53.
16. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382-9.
17. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36:1062-7.
18. Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45:843-9.
19. Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 2003; 37:e8-11.
20. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis 2002; 35: 347-8.
21. Nimeiri HS, Nemiary DS. Challenges with linezolid therapy and reversible pancytopenia. Ann Hematol 2003; 82:533.
22. Hansen NE, Karle H, Valerius NH. Neutrophil kinetics in acute bacterial infection: a clinical study. Acta Med Scand 1978; 204:407-12.
23. Jung U, Norman KE, Scharffetter-Kochanek K, Beaudet AL, Ley K. Transit time of leukocytes rolling through venules controls cytokine-induced inflammatory cell recruitment in vivo. J Clin Invest 1998; 102: 1526-33.
24. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37:1609-16.
25. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47:1824-31.